文献速递淋巴瘤造血干细胞移植与细胞治疗

移植合格的原发性中枢神经系统淋巴瘤:高强度诱导无生存获益且毒性增加

Induction intensity in transplant-eligible primary CNS lymphoma: no survival benefit despite increased toxicity.
PubMed 文献 · Blood Adv · 2026-09-24

这项国际多中心回顾性研究纳入355例移植合格的原发性中枢神经系统淋巴瘤患者,比较MATRix、R-MPV/R-MT和减强度Alberta方案诱导。三种方案移植率和2年生存率相似,但MATRix的剂量减少、ICU入住和治疗相关死亡率更高,提示减强度诱导可在不损害长期结局下改善耐受性。

要点

  • 三种诱导方案的移植率和2年生存率无显著差异
  • MATRix方案毒性显著更高,包括剂量减少、ICU入住和治疗相关死亡
  • 减强度诱导方案可达到与MATRix相当的移植和生存结局,且耐受性更优

核心结论

  • 减强度诱导方案在移植合格的原发性中枢神经系统淋巴瘤患者中达到与MATRix相当的移植率和生存结局,且耐受性更优。

研究设计与样本

  • 国际多中心回顾性研究,纳入11个中心的355例移植合格患者,分别接受MATRix(n=164)、R-MPV/R-MT(n=121)或减强度Alberta方案(n=70)。

主要发现

  • 总体缓解率为89.5%,完全缓解率为50.1%。
  • MATRix、R-MPV/R-MT和Alberta组的移植率分别为74.4%、69.4%和78.6%(p=0.36)。
  • 三组2年总生存率分别为79.0%、89.0%和82.1%(p=0.32),2年无进展生存率分别为63.7%、72.6%和75.3%(p=0.26)。
  • 接受移植的患者(n=261)中亦观察到相似结局。
  • MATRix与更高的剂量减少率(p=0.006)、ICU入住率(p<0.001)和治疗相关死亡率(p=0.006)相关。

临床怎么用

  • 对于移植合格的原发性中枢神经系统淋巴瘤患者,可考虑选择减强度诱导方案以优化耐受性而不损害长期结局。

局限性

  • 回顾性研究设计可能存在选择偏倚和混杂因素,尽管采用了逆概率治疗加权调整基线不平衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary central nervous system lymphoma is an aggressive lymphoma for which high-dose chemotherapy followed by autologous stem cell transplantation is standard first-line treatment in eligible patients; however, the optimal induction regimen remains uncertain. We conducted a multicenter international retrospective study across 11 centers including 355 transplant-eligible patients treated with MATRix (n=164), R-MPV/R-MT (n=121), or the reduced-intensity Alberta protocol (n=70). The overall response rate was 89.5%, with a complete response rate of 50.1%. Although complete response rates were higher with R-MPV/R-MT, transplantation rates were similar across regimens (74.4%, 69.4%, and 78.6%, respectively; p=0.36). Two-year overall survival was 79.0%, 89.0%, and 82.1% (p=0.32), and 2-year progression-free survival was 63.7%, 72.6%, and 75.3% (p=0.26) for MATRix, R-MPV/R-MT, and Alberta, respectively. Comparable outcomes were also observed among patients proceeding to transplantation (n=261). Toxicity however differed substantially between regimens: MATRix was associated with higher rates of dose reductions (p=0.006), ICU admissions (p<0.001), and treatment-related mortality (p=0.006). After adjustment for baseline imbalances using inverse probability of treatment weighting, survival outcomes remained comparable across treatment groups, whereas MATRix retained a less favorable toxicity profile. Less intensive induction regimens achieved transplantation and survival outcomes comparable to MATRix while demonstrating superior tolerability, supporting treatment strategies that optimize tolerability without compromising long-term outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zeremski V, Lee JO, Puckrin R, et al. Induction intensity in transplant-eligible primary CNS lymphoma: no survival benefit despite increased toxicity. Blood Adv. 2026. PMID: 42782308. doi:10.1182/bloodadvances.2026021352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。